BOLT BIOTHERAPEUTICS INC (BOLT)

US0977021049 - Common Stock

0.7355  +0 (+0.07%)

News Image
5 days ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT). Such...

News Image
21 days ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT). Such...

News Image
a month ago - InvestorPlace

The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows

Explore key stocks with analyst uncertainty to avoid amid contrasting global market highs and risky downgrades.

News Image
a month ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT). Such...

News Image
a month ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT). Such...

News Image
a month ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings worth watching this morning!

News Image
a month ago - InvestorPlace

BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q1 2024

BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Image
a month ago - BusinessInsider

BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bolt Biotherapeutics (NASDAQ:BOLT) just reported results for the first quarter ...

News Image
3 months ago - InvestorPlace

BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023

BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

News Image
3 months ago - BusinessInsider

BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bolt Biotherapeutics (NASDAQ:BOLT) just reported results for the fourth quarter...

News Image
3 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

–   BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones–   BDC-3042 Phase 1 study...

News Image
4 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel...

News Image
7 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and...

News Image
7 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023, and provided an update on the continued advancement of its clinical programs.

News Image
8 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D)Improved efficacy with one partial response (PR) improving...

News Image
8 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion...

News Image
8 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering...

News Image
9 months ago - Seeking Alpha

Bolt Bio stock spikes on FDA’s orphan status (NASDAQ:BOLT)

Bolt Biotherapeutics gains FDA's Orphan Drug Designation for BDC-1001, an immune-stimulating antibody conjugate for the treatment of gastric cancer. Read more here.

News Image
9 months ago - Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and...